EPIVAX - Key Persons
Job Titles:
- Director of Bioinformatics
Aimee manages a team of analysts and project managers providing in silico immunogenicity risk assessments supporting research, collaborative, and commercial projects.
Job Titles:
- Immunologist
- Physician
- Senior Director of Immunology and Protein Therapeutics
Amy Rosenberg is a physician immunologist with extensive expertise in
Anne De Groot is internationally known for her research on the human immune system's response to vaccines and therapeutics. She graduated from Smith College in 1978 and earned her medical degree at University of Chicago in 1983. After internal medical residency, she obtained advanced training in immunoinformatics and vaccinology with Michael Good, Russell Howard and Jay Berzofsky at the National Institutes of Health, and then returned for a fellowship in ID at New England Medical Center.
Job Titles:
- Laboratory Manager
- Manager
Bethany McGonnigal is the Laboratory Manager at EpiVax, Inc. Beth obtained her Bachelor of Science Degree from Bridgewater University. She came to EpiVax via UC Irvine, where she worked as the Laboratory Manager and Senior research associate for Dr. Aaron Esser-Kahn. While there, she facilitated the development and studies of TLR based adjuvants and other immune modulatory molecules and peptides. Beth is delighted to be back in Providence and contributing to the successes of the RI Biotech community.
Job Titles:
- Scientific Director of the Preclinical Immunology
- Scientific Director, Preclinical Immunology
Brian Roberts is the scientific director of the Preclinical Immunology program. Dr. Roberts received his PhD in Cell and Molecular Biology from the University of Vermont in 2012. His research in the laboratory of Dr Sally Huber focused on the role of toll-like receptors in sex differences in viral-induced autoimmune myocarditis. Dr. Roberts joined EpiVax in 2015 as a postdoctoral researcher working primarily with the Tregitope team. In 2018 he became manager of the Protein Therapeutics group at EpiVax, and oversees the PANDA projects.
Cliff joined EpiVax, Inc. in the summer of 2007 as the Associate Director of Finance. Soon after joining EpiVax, Cliff earned his MBA from the University of Phoenix. During his tenure, Cliff's responsibilities have continuously evolved. Currently, he represents EpiVax as the Managing Director. In this role, Cliff leads all aspects of operations to include strategy development and execution.
In his early years at EpiVax, Matthew Ardito assisted in maintaining applications associated with the design and reengineering of protein therapeutics and antibody structures, as well as genome mining, epitope mapping, and vaccine design. In 2016, Matt was promoted to Principal Applications Developer and Codebase Manager, where he led a team of developers in the design, development, implementation, testing, and deployment of immunoinformatics applications. In 2021, Matt was promoted again to Director of IT, where he is responsible for the management, strategy, and execution related to the maintenance of IT infrastructure at EpiVax.
Matthew Ardito joined EpiVax in the Spring of 2008, two days after obtaining his Bachelor's in both Computer Science and Mathematics at Rhode Island College. In his early years at EpiVax, Matt assisted in maintaining applications associated with the design and reengineering of protein therapeutics and antibody structures, as well as genome mining, epitope mapping, and vaccine design. As the lead analyst, he used in-silico tools and custom made driver scripts for client- and grant-based projects ranging from predicted antibody/therapeutic immunogenicity and deimmunization to the formulation of genome-derived, epitope-driven vaccines. In 2016, Matt was promoted to Principal Applications Developer and Codebase Manager, where he led a team of developers in the design, development, implementation, testing, and deployment of immunoinformatics applications relevant to ISPRI (antibody re-engineering pipeline), IVAX (epitope-based vaccine design pipeline), ISPRI_HCP (host cell protein immunogenicity), matrix development, and ANCER (personalized cancer vaccine) web platforms. In 2021, Matt was promoted again to Director of IT, where he is currently responsible for the management, strategy, and execution related to the maintenance of IT infrastructure at EpiVax. Matt oversees all IT functions including, but not limited to: designing, securing and implementing information systems, leading the growth and expansion of all internal application development, devising and establishing all IT-related policies and procedures, and supervising a team of IT professionals tasked with ensuring the company's technology operations run efficiently.
Liu, Wei, Oliver Dienz, Brian Roberts, Mohamad Moussawi, Mercedes Rincon, and Sally A. Huber. "IL-21R expression on CD8+ T cells promotes CD8+ T cell activation in coxsackievirus B3 induced myocarditis." Experimental and molecular pathology 92 no. 3(2012): 327-333
Job Titles:
- CIO
- COO
- Principal Architect and Developer
William Martin is the principal architect and developer of the EpiMatrix System. Building on the work done in Dr. De Groot's Brown University laboratory, Mr. Martin has revised and expanded the EpiMatrix toolkit. In addition to developing new and improved predictive matrices for many Class I and Class II HLA alleles, Mr. Martin has developed a suite of protocols, ancillary tools and database structures allowing for fast and efficient analysis of input protein sequences.